Skip to main content
OpenTrials
Completed

NCT Number: NCT03156998

Patients' Compliance to Home Nebulizer Therapy for Children's Asthma in China

An observational study to investigate the compliance of home nebulizer therapy among children aged 0-14 years old clinically diagnosed with asthma

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 14 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Facility, Bengbu, Anhui, China

Loading trial locations.

About this study

Asthma is the most common chronic disease of childhood and the leading causes of childhood morbidity from chronic disease (GINA 2016). It is clear that inhaled corticosteroid (ICS) is foundation of asthma treatment and recommended both in Global Initiative for Asthma (GINA) and Chinese paediatric asthma diagnosis and treatment guideline. But the well-controlled rate of asthma was not ideal. National Parents of Asthmatic Children KAP Project Team (China) showed that 66.0% asthmatic children had asthma attacks in the past 12 months, 26.8% asthmatic children had visited the emergency department and 16.2% asthmatic children had been hospitalized. (Asthmatic Children KAP project team, 2013) .A few studies showed an increased risk of uncontrolled asthma or an asthma exacerbation in children with lower compliance (Jentzsch NS, 2012; Milgrom H, 1996). Poor compliance to inhaled corticosteroids may also contribute to poor asthma control level and asthma mortality (GINA 2016). Home nebulizer therapy has been recommended in GINA and Chinese Paediatric asthma diagnosis and treatment guideline. Compare to other inhalers, delivering ICS through nebulizer therapy need minimal patient's cooperation and normal breathing pattern (Deborah Elliott, 2011), but there are no studies to show the compliance of home nebulizer therapy in Chinese clinical practice. So we aim to investigate the compliance to home nebulizer therapy, and try to explore the related risk factor with poor compliance in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 0-14 years old, clinical diagnosed as asthma according to Chinese paediatric asthma diagnosis and treatment guideline
  • Prescribed home nebulizer therapy for at least 3 month
  • The guardians must sign the Informed Consent Form; Subjects who can make decision by him/herself must also sign the Informed Consent Form

Diagnosis of paediatric asthma:

The patient who fulfil criteria 1 to 4 or criteria 4 plus any item of criteria 5 could be diagnosed as paediatric asthma.

  • Recurrent respiratory symptoms (wheeze, cough, dyspnoea, chest tightness), typically worse at night/early morning, exacerbated by exercise, viral infection, smoke, dust, pets, mold, dampness, weather changes, laughing, crying, allergens.
  • A musical, high-pitched whistling sound could be detected in both sides of the lung by auscultation of the chest. The wheezing is usually during exhalation.
  • Symptoms/signs above could be relieved automatically or by anti-asthmatic treatment.
  • Exclusion of the other diseases, which also could cause wheeze, cough, dyspnoea, chest tightness.
  • Atypical symptoms/signs without any wheeze or whistling sound (at least fulfil one of the following criteria):
  • The results of bronchial provocation test is positive. 2) Demonstrating reversible airflow limitation: i. The result of bronchial dilation test is positive. ii. Anti-asthmatic treatment is effective for lung function improvement. 3) The ratio of daily variation of PEF (consecutively more than two weeks) is more than 13%.

Exclusion criteria

  • Allergy to any inhaler cortical steroid
  • Presenting with differential diagnosis of asthma such as congenital heart disease, gastro-oesophageal reflux, bronchopulmonary dysplasis, bronchiolitis obliterans, etc
  • Parents/Guardian have problem in expression, understanding, writing and reading in Chinese judged by the investigator
  • Subjects are participating other on-going clinical studies
  • Subjects with other diseases that may interfere the study results judged by the investigators

Treatment and study plan

Primary outcomes

  1. Median treatment compliance (%) derived using actual treatment frequency (monitored by electronic chips) divided by prescribed frequency

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

Secondary outcomes

  1. Proportion of patients in different treatment compliance levels (<50%, 50 %≤-< 80%, 80%≤-≤120%, >120%) monitored by electric chips

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  2. Median treatment compliance (%) reported by caregivers derived using actual doses divided by prescribed doses

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  3. Proportion of patients in difference compliance levels reported by caregivers

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  4. Proportion of patients by severity

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  5. Factors associated with treatment compliance

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  6. The proportion of asthma control status (controlled, partly controlled and uncontrolled asthma) according to GINA 2016 definition at visit 2 to 4 overall and by compliance level.

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  7. The proportion of asthma control status according to TRACK for subjects under 5 years old

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  8. Factors associated with control levels (controlled, partly controlled and uncontrolled asthma)

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

Other outcomes

  1. Direct health expenditure of asthma treatment and management

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  2. caregiver's loss of working days

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

  3. children's loss of kindergarten/school days

    Time frame: From 3 June 2017 to 3 March 2018, an expected average of 3 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Patients' Compliance to Home Nebulizer Therapy for Children's Asthma in China An Observational Study to Investigate the Compliance of Home Nebulizer Therapy Among Children Aged 0-14 Years Old Clinically Diagnosed With Asthma

Acronym: CARE

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
May 17, 2017
Registry last updated
Apr 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.